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Abstract: In the pathogenesis of chronic otitis media (COM), much attention is paid to the molecular mechanisms
of local inflammatory reactions in which mast cells (MCs) may be involved due to their role not only in allergic but
also inflammatory processes. The aim of this study was to assess the density of mast cells in chronic otitis media in
relationship to different clinical courses of COM, bacterial infections and types of disease. The MCs expression
was measured immunohistochemically in paraffin-embedded granulation tissue specimens taken during surgery,
by staining with a monoclonal antibody against tryptase. The density of tryptase-positive mast cells was lower in
tissue samples from the group with a good clinical course than in those from the group with poor healing and
recurrence (p = 0.006). There were no differences between the groups of patients with granulomatous and cho-
lesteatomatous chronic otitis media (p = 0.66) or between the groups of patients with and without bacterial infec-
tion (p = 0.30), although the density of mast cells was lower for those with Pseudomonas aeruginosa/Proteus sp./
/Staphyloccocus MRSA infection. In conclusion, the expression of mast cells in chronic otitis media granulation
tissue was found to differ depending on the clinical course of the disease, but not on bacterial infection or type of
COM. This may suggest that mast cells contribute to the maintenance of the inflammatory process, but not to
antibacterial defense in chronic otitis media. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 479–485)
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Introduction
Chronic otitis media (COM) is defined as permanent
inflammatory disease in the middle ear and mastoid
cavity with the presence of tympanic membrane per-
foration, discharge from the ear and often a prolifer-
ative process of the mucosal lining in the form of gran-
ulation tissue, polyp or cholesteatoma. It is one of
the most important causes of acquired hearing loss.
In recent years, more attention has been paid to mo-
lecular mechanisms of local inflammatory reactions
in the pathogenesis of COM [1]. Typically, polymor-
phonuclear neutrophils, macrophages and their me-
diators take part in the chronic inflammatory process.
Growing evidence points to the role of mast cells
(MCs) not only in allergic but also in inflammatory
reactions [2, 3]. This possible function of mast cells is
associated with their specific localization closely to
the external environment, their long life, and a wide
spectrum of mediators stored in the granules of MCs
[4]. It has been postulated that they are involved in
chronic inflammatory diseases such as asthma, rheu-
matoid arthritis, coronary disease, bullous pemphig-
oid, interstitial cystitis, chronic bowel and intestinal
diseases and multiple sclerosis [5, 6].
Mastocytes participate in nonspecific immunolog-
ical mechanisms in host defense against pathogens.
They can phagocytize bacteria and release pro-inflam-
matory mediators due to contact with bacteria and
their products [3, 4]. Mastocytes can also regulate the
adaptive immunity to infection by modulation of den-
dritic cell and T-cell responses [3, 7, 8] and contrib-
ute to tissue remodeling in chronic inflammation [9].
Mast cells are distributed abundantly in skin, lym-
phatic organs, mucosa of gastrointestinal and respi-
ratory tracts. They are also present in middle ear
mucosa in both animals and humans, especially in pars
flaccida of tympanic membrane, in tubotympanum
and pharyngeal ostium of Eustachian tube [10, 11].
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In the middle ear, the highest density of MCs has been
reported in well vascularized mucosa or mucosa cov-
ered by ciliated epithelium [11]. MCs are more abun-
dant in the epithelium than in the subepithelial layer,
as compared to adenoid [12].
The role of mast cells and their mediators, such as
tryptase and histamine, has been assessed in pathol-
ogy of the middle ear mainly in adenoid hypertrophy
and otitis media with effusion (OME) [13–17]. Some
studies have found increased number of MCs and
higher levels of histamine in adenoid, which may
indicate that mast cells are the source of inflamma-
tory mediators for Eustachian tube and middle ear
[13–15]. Increased counts of MCs and elevated
tryptase levels, in effusion and in middle ear mucosa,
have been demonstrated in allergic patients with OME
[16, 17]. Clinical studies reporting high histamine lev-
els in middle ear effusion in secretory otitis media
[12, 18] and in acute otitis [19], as well as experimental
studies of guinea pigs in which histamine injection into
the tympanic cavity had caused long-standing effusion
[20], also point to histamine participation in the path-
omechanism of middle ear inflammation.
Mast cells have rarely been investigated in chron-
ic otitis media and only a few studies about their par-
ticipation in cholesteatoma are accessible. There are
none dealing with the clinical features in COM. Albi-
no et al. [21] found a 3- to 7-fold increased number of
MCs in different types of cholesteatoma, more intense
in a primary acquired one, and their localization was
typical for intensive inflammatory process. The pres-
ence of tryptase and chymase has been reported in
middle ear cholesteatoma, pointing to a participation
of MCs proteases in the pathogenesis of the disease
[22]. Sankovic et al. [23] found MCs in nearly all mid-
dle ear biopsies, although they were degranulated to
a lesser extent in COM (37.8%) than in OME (81.8%).
Therefore, investigating the possible influence of
mast cells on the outcome of COM, as an example of
chronic inflammation, seems important. This is why
the aim of our study was to assess the density of mast
cells in granulation tissue in chronic otitis media and
evaluate their participation in postoperative healing
and recurrence of the disease, in concomitant bacte-
rial infection, and in a type of COM.
Material and methods
Characteristics of study groups. Fifty-four patients (33
men, 21 women) with chronic otitis media, who had under-
gone surgical treatment, were enrolled into the study. The
mean age was 46.4 ± 15.6 years, ranging from 19 to 77 years.
All patients were assessed prior to surgery and operated on
by the same surgeon (T.D.). Twenty one patients were sub-
jected to radical mastoidectomy and 33 patients to radical
modified mastoidectomy. Both operations are open (canal
wall down) approaches, so the posterior canal wall between
the tympanic cavity and the mastoid process is removed to
improve drainage and aeration of middle ear cavities. The
radical mastoidectomy is an extended type of operation in
which all damaged tympano-ossicular elements (tympanic
membrane, malleus, incus) are removed, in contrast to rad-
ical modified mastoidectomy, in which those which are still
working are preserved during surgery and may serve for tym-
panoplasty [24]. The degrees of COM severity were nearly
similar in this sample since the patients were subjected to
types of operation, which are based on the same surgical
strategy intended to avoid recurrence. Both of these opera-
tions are used in more advanced stage of COM.
The study group was divided according to clinical course
of disease as follows:
— group NR (no recurrence) — consisted of 25 patients
(mean age 50.8 ± 17.8 years, 11 women) with a good
clinical course, ear cavity healed well postoperatively
and epithelialised after three months, there was no long-
-term discharge or recurrence of inflammation during
five-year follow-up;
— group R (recurrence) — consisted of 29 patients (mean
age 42.7 ± 12.6 years, ten women) with poor postope-
rative healing and recurrence of disease during five-
-year follow-up.
The patients were divided also according to coexistence
and type of bacterial infection into three groups:
— group B0 (n = 14 patients) — with no concomitant bac-
terial infection;
— group B1 (n = 20 patients) — with Pseudomonas aeru-
ginosa/Proteus sp./Staphyloccocus MRSA infection
which constitute a separate group, as these bacteria are
typical for COM but very difficult to eradicate. In group
B1, Pseudomonas aeruginosa was the most frequent pa-
thogen (17 patients, in one case coexistent with Staphy-
lococcus aureus), Proteus sp. was noted in two patients
and Staphylococcus aureus MRSA in one patient;
— group B2 (n = 20 patients) — with bacterial infection
different to that in group B1. In group B2, the follo-
wing bacteria were found: Dyphteroides sp. — five pa-
tients (coexistent with Escherichia coli ESBL (–) — two
patients), Staphylococcus epidermidis — four patients,
Staphylococcus aureus — ten patients (coexistent with
Streptococcus pneumoniae — one patient) and Esche-
richia coli ESBL (–) — one patient. Fungal infection
by Candida parapsilosis was observed as concomitant
with a bacterial one, in one case with Staphylococcus
aureus, and in one case — with Pseudomonas aerugi-
nosa and Staphylococcus aureus.
The study group was divided according to type of COM into:
— group G — granulomatous type, without cholesteatoma
(n = 38 patients, mean age 46.8 ± 15.6 years, 16 women);
— and group CH — cholestatomatous type (n = 16 pa-
tients, mean age 45.6 ± 16.0 years, five women).
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Group R was younger than group NR (42.7 vs. 50.8 years
respectively, p = 0.057) and Pseudomonas aeruginosa/Proteus
sp./Staphyloccocus MRSA infection was more frequently found
in this group (55.2% vs. 16% respectively, p = 0.002).
Moreover, bacterial infection (both from B1 and B2
groups) was observed more often in the cholesteatoma
group than in the granulomatous group (93.8% vs. 65.8%
respectively, p = 0.003). The recurrence of COM was mostly
observed in the B1 group followed by the B0 and then the
B2 (80% vs. 42.9% vs. 35%, respectively, p = 0.003). Nearly
the same percentage of good and poorer clinical course was
observed in both types of COM (no recurrence in G and
CH groups: 47.4% vs. 43.7%, respectively).
The Bioethics Committee of the Medical University of
Lodz approved the study protocol (Document No. RNN/
/57/09/KE).
Tissue samples. The density of mast cells was evaluated
immunohistochemically by assessing tryptase activity in gran-
ulation samples removed during surgery from the tympanic
cavity. Sections were prepared from formalin-fixed, paraf-
fin-embedded material. In all specimens, the presence of
granulation tissue was confirmed by a histopathologist
(M.D.). In the pilot study, we identified mast cells in granu-
lation tissue with toluidine blue staining and about half of
them were degranulated.
Moreover, in all patients, the bacteriological examina-
tion to aerobes and fungi was made. The smears were ob-
tained using sterile cotton swabs, then placed on agar plates
for incubation, and identified. The tests determining phe-
notypes and mechanisms of resistance of isolated patho-
gens were also performed (MRSA, ESBL, HLAR, MLSB,
MBL, VISA/VRSA).
Immunohistochemistry (IHC). For immunohistochemical
assay, 4 μm paraffin sections were mounted onto superfrost
slides, deparaffinated in a sequence of xylene, dehydrated
in a series of alcohols and rinsed twice in distilled water.
Antigen was treated with 0.01 M citrate buffer, pH 6.0
(DAKO, Target Retrieval Solution) by heating in a micro-
wave oven (parameters: 360 W — 2 × 3 minutes, 180 W —
2 × 5 minutes and 90 W — 2 × 5 minutes). After cooling,
sections were rinsed twice in 0.05 M buffer TRIS (TBS,
DAKO), pH 7.6 for 5 minutes and incubated with 3% hy-
drogen peroxide (H2O2) for 10 minutes in order to block
endogenous peroxidase activity. Then monoclonal mouse
anti-human Mast Cell Tryptase (Clone AA1, Dako Cyto-
mation, Glostrup, Denmark, dilution 1:100) was applied.
The sections were incubated for 1 hour with primary anti-
body diluted with DAKO Antibody Diluent with Back-
ground Reducing Components in a humid chamber at room
temperature. Afterwards, sections were rinsed twice in TBS
and visualisation system EnVision/HRP/DAB+ (DAKO
Cytomation, Glostrup, Denmark) was used according to the
manufacturer’s instruction. After 30 minutes’ incubation
with horseradish peroxidase-conjugated secondary antibod-
ies, the positive immunoreactivity was visualised using 3,3'-
-diaminobenzidine tetrachloride (DAB) as chromogen. Af-
ter washing in distilled water, sections were counter-stained
with hematoxylin and coverslipped. Negative controls were
carried out by incubation in the absence of the primary an-
tibody, and always yielded negative results.
Morphometry. Staining of tryptase-positive mast cells was
evaluated using a computer image analysis system consist-
ing of a PC equipped with a Pentagram graphic tablet, an
Indeo Fast card (frame grabber, true-color, real-time) pro-
duced by Indeo (Taiwan), and a color TV camera produced
by Panasonic (Japan) coupled with a Carl Zeiss microscope
(Germany). This system was programmed (MultiScan 8.08
software, produced by Computer Scanning Systems, Poland)
to calculate the number of objects (automatic or semi-au-
tomatic function).
The density of tryptase-positive mast cells was evaluated
using automatic function of MultiScan, with manual correc-
tion as needed. The 8–10 monitor fields (0.029 mm2 each)
were analyzed according to the size of the section. The re-
sults were expressed as the mean number of tryptase-posi-
tive mast cells per mm2 of the section. The example of tryptase-
positive mast cells expression is presented in Figure 1.
Data analysis and statistics. Statistical analysis was per-
formed by Statistica version 6.0 software. Data was expressed
as means ± standard deviation (SD). Data was checked for
normality by the Shapiro–Wilk test and for the homogene-
ity of variance by Levene’s test. The Mann–Whitney U test
and one-way analysis of variance (ANOVA) were applied
for comparison of groups. A two-way repeated-measures
Figure 1. Tryptase-positive mast cells in granulation tissue
in patient with poor clinical course of chronic otitis media.
Immunostaining with anti-tryptase monoclonal antibody,
magnification × 400
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ANOVA with post-hoc LSD Fisher test, if appropriate, were
carried out on the density of mast cells for the following
factors: clinical course of COM (no recurrence–recurrence),
presence and type of bacterial infection, type of COM (gran-
ulomatous – cholesteatomatous). The differences were con-
sidered statistically significant when p was less than 0.05.
Results
In the whole group with chronic otitis media, the mean
density of tryptase-positive mast cells was 102.1 and
ranged from 2.0 to 137.2 per mm2 of the section. The
mean value of tryptase-positive MCs was significant-
ly lower in the COM group with a good clinical course
compared to the group with recurrence of disease
(94.9 vs. 108.3 respectively, p = 0.006) (Table 1). There
were no significant differences in the mean density of
tryptase-positive MCs between groups with and with-
out concomitant bacterial infection (one-way ANO-
VA p = 0.30); however, the Pseudomonas aeruginosa/
/Proteus sp/Staphyloccocus MRSA group had lower
values than the B0 and B2 groups (95.6 vs. 109.2 vs.
103.7 respectively; post hoc tests: groups B0–B1: p =
= 0.13, B0–B2: p = 0.54, B1–B2: p = 0.32). Similar-
ly, there were no significant differences between the
granulomatous and cholesteatomatous types of COM
(p = 0.66).
The results of two-way ANOVA revealed that
there was a significant main effect only for clinical
course of COM (F = 7.97; df = 1; p = 0.007) and
a tendency to main effect on presence and type of
bacterial infection (F = 3.04; df = 2; p = 0.057), but
the interaction effect between these factors was not
significant (p = 0.98) (Figure 2). The two-way ANO-
VA showed no interaction between clinical course and
type of COM (p = 0.28) or between type of COM
and bacterial infection (p = 0.36).
Discussion
Our study assessed the participation of mast cells
in chronic otitis media in relationship to some clin-
ical features of the disease such as course, concom-
itant bacterial infection and type of COM. We used
one of the human MCs’ serine proteases, i.e.
tryptase, which occurs in several types, including
b-tryptase which is the main type stored in MCs’
secretory granules. Tryptase occurs almost exclu-
sively in mast cells and in trace amounts in baso-
philes, so it is considered as a reliable marker of
MCs’ activation [25].
Table 1. Mean values of tryptase-positive mast cells density in granulation tissue in different groups of patients with
chronic otitis media (n = 54)
Mast cells (number/mm2) Range (min–max) Mean ± SD p
Whole group (n = 54) 2.0–137.2 102.1 ± 25.7
Group NR (n = 25) 46.1–134.7 94.9 ± 24.1 0.006
Group R (n = 29) 2.0–137.2 108.3 ± 25.8
Group B0 (n = 14) 68.2–137.2 109.2 ± 22.4 0.30
Group B1 (n = 20) 2.0–132.9 95.6 ± 30.1
Group B2 (n = 20) 72.1–136.3 103.7± 22.5
Group G (n = 38) 46.1–137.2 103.8 ± 22.5 0.66
Group CH (n = 16) 2.0–132.9 98.2 ± 32.6
Group N — good clinical course of chronic otitis media (COM); group R — recurrence of COM; group B0 — without bacterial infection;
group B1 — with Pseudomonas aeruginosa/Proteus sp./Staphyloccocus MRSA infection; group B2 — with bacterial infection different to
that of group B1; group G — granulomatous COM; group CH — cholestatomatous COM
Figure 2. Tryptase-positive mast cell density
(mean ± SEM) in groups compared by clinical course of
chronic otitis media and bacterial infection;
SEM — standard error of mean
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Our study found that patients with poorer post-
operative healing and recurrence had significantly
higher density of tryptase-positive mast cells than
those with a good clinical course of chronic otitis
media. This may suggest that mastocytes contribute
to the maintenance of the inflammatory process. The
role of mast cells in chronic inflammation is not fully
understood. It has been reported that they are in-
creased in inflammatory processes but there is con-
tradictory evidence of their effect i.e. protective or
deleterious [6]. This dual role of MCs in modulating
inflammatory responses is realized by different mech-
anisms [26]. They release a wide range of mediators,
such as preformed mediators, de novo synthesized
mediators and cytokines, which can regulate inflam-
mation [27]. Mastocytes are implicated in the recruit-
ment and activation of neutrophils, monocytes/mac-
rophages, and other inflammatory cells to sites of in-
fection [6, 28], in directing effector T cells and den-
dritic cells [29, 30] and in interplay with regulatory
T cells [31]. They act also as epithelial and fibroblast
mitogen in inflammatory tissue remodeling [32, 33]
and in angiogenesis due to releasing heparin, hista-
mine and angiogenic cytokines [5]. In middle ear struc-
tures, it has been shown that mast cells’ degranula-
tion causes the inflammatory reaction of tympanic
membrane [34]; however they may also contribute to
healing of tympanic membrane perforations in acute
otitis media [35]. It has also been demonstrated on
the animal model of middle ear otitis that early in-
flammatory reaction to Haemophilus influenzae was
less pronounced in W/Wv mice which did not exhibit
proto-oncogene c-kit expression, so did not have mast
cells, than in wild-type mice and W/Wv mice after
reconstitution of MCs [36].
Bacterial infection often causes an exacerbation
in the clinical course and failure in treatment in chron-
ic otitis media. This was seen in our study in the group
with Pseudomonas aeruginosa/Proteus sp./Staphyloc-
cocus MRSA in which recurrence was twice as fre-
quent as in other groups. Bacterial toxins may acti-
vate MCs which, in response to infection, release
many mediators causing an increase in vascular per-
meability and in the expression of adhesion molecules
or act chemotactically directly on neutrophils and
eosinophils, and also produce anti-microbial peptides
like cathelicidins and defensins. Activation of human
mast cells has been demonstrated for Staphylococ-
cus aureus and Pseudomonas aeruginosa, which are
the most common isolates from chronic otitis media
[37–40]. Chonmaitree et al. [19] reported that hista-
mine levels were higher in bacteria-positive than bac-
teria-negative effusions in acute otitis media. Our
study, however, failed to show any significant differ-
ence in density of MCs in relationship to bacterial
infection or to demonstrate its protective antibacte-
rial role in the chronic inflammatory process. Inter-
estingly, the lowest mean density of mast cells both in
N and R groups was observed in an infection that was
more difficult to eradicate (Pseudomonas aeruginosa/
/Proteus sp./Staphyloccocus MRSA). It is plausible
that the persistent inflammation caused by more re-
sistant bacteria has exhausted MCs’ proinflammato-
ry abilities. The possible mechanisms observed in
Pseudomonas aeruginosa infection may be due to
mast cell apoptosis induced by exotoxin A [41] or
modulation of MCs’ activity and the release of cytok-
ines by quorum sensing in biofilms [42], which have
also been shown in cholesteatoma [43].
In the current study, we have hypothesized that
mast cells are likely to show higher activity in cho-
lesteatoma which is considered as a more aggressive
type of COM because of the frequent destruction of
adjacent bone and soft tissues. Berger et al. [44] have
postulated that mast cells may play a role in bone re-
sorption in COM as they were increased in tissues
close to eroded ossicles. MCs may also release medi-
ators like TNF-a, IL-b or N-acetylo-b-D-hexosoam-
inidase known to participate in bone destruction in
cholesteatoma [45, 46]. However, in our study, the
fact that there was no difference in the mean densi-
ty of mast cells between both types of COM sug-
gests that they did not contribute more to choleste-
atoma. Although our immunohistochemical exami-
nation was performed in granulation tissue close to
cholesteatoma and not in its perimatrix, it seems that
participation of mast cells in otitis media is related
to the chronicity of inflammatory process, rather than
its type.
Conclusions
The results of our study show that density of tryptase-
positive mast cells in granulation tissue in chronic
otitis media differs depending on clinical course, but
not on bacterial infection or type of disease. It may
suggest that mast cells contribute to the maintenance
of inflammatory process, but not to antibacterial de-
fense in chronic otitis media.
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